InflaRx provides update on planned Phase III study design in pyoderma gangrenosum with vilobelimab and status of its EUA application in critically ill COVID-19 patients
You are currently viewing a placeholder content from Elfsight. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
